AEYE Diagnostic Screening (AEYE-DS) allows primary care providers to screen their diabetic patients for diabetic retinopathy using AI technology instead of referring them to specialists. AEYE-DS is FDA-cleared based on a large scale clinical study. Screening patients requires a single image per eye, and produces a result instantly and with best-in-class accuracy (Sensitivity 93%; Specificity 91.4%).

AEYE Health provides the only practical AI-based diagnostic screening solution for diabetic retinopathy. The procedure is reimbursable by primary care providers using a dedicated CPT code 92229.

Diabetic retinopathy screenings are required once a year for patients with diabetes. Studies show that less than 50% of patients make their annual screening appointments, which translates into significant care gaps and poor patient outcomes.

AEYE Health Diagnostic Screening

Autor: Aeye Health, Inc.